

Imugene progresses mimotope platform with filing of new patent applications

MELBOURNE Australia, 19 December 2016: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, today announced the filing of four new patent applications with IP Australia that if granted, will provide cover until 2037¹.

Three of the patents filed under the name of Imugene Ltd specifically protect new mimotope B-cell vaccine compositions which are directed to commercially validated immuno-oncology targets. Each of the targets already has a monoclonal antibody synthetic drug on market generating sales in the hundreds of millions treating cancers such as melanoma, non-small cell lung cancer, multiple myeloma and bladder cancer. A fourth patent filed under the name of the Medical University of Vienna protects a broad technology platform related to identifying mimotopes from available monoclonal antibodies.

Imugene Chief Executive Officer Leslie Chong said, “Maintaining and strengthening our already strong international intellectual property position is a key area of focus in maintaining the competitive advantage of our B-cell mimotope peptide vaccine portfolio. We are extremely pleased with the progress made from our expert scientific team in 2016.”

For further information please contact:

Leslie Chong
Chief Executive Officer
T: +61 458 040 433

Paul Hopper
Executive Chairman
T: +61 406 671 515

About Imugene

Imugene (ASX: IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based

immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.

In January 2016 Imugene announced a new partnership with the Medical University of Vienna to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create B Cell peptide vaccines that would replace or augment conventional monoclonal antibodies.

¹ IP Australia patent number, filing and title details:

1. Patent 2016905221, filed in the name of Imugene Ltd, "A vaccine composition and uses thereof"
2. Patent 2016905222, filed in the name of Imugene Ltd, "A vaccine composition and uses thereof"
3. Patent 2016905224, filed in the name of Imugene Ltd, "A vaccine composition and uses thereof"
4. Patent 2016905223, filed in the name of Medizinische Universitaet Wien, "A method of producing a vaccine composition and uses thereof"

For further information, please visit www.imugene.com.

Sign up to follow @TeamImugene on Twitter at <http://www.twitter.com/TeamImugene>.

To follow Imugene on Facebook visit www.facebook.com/imugene.